MENU

X-Editor (XE): Engineering Cas12e for High-Potency In Vivo Editing

bioRxiv USA
Overview
Researchers have developed the X-Editor (XE), a compact nuclease platform derived from Cas12e that exhibits over 100-fold higher editing activity in human cells than its predecessor. Tested in nonhuman primate livers via lipid nanoparticles, XE achieved greater editing at lower doses than comparable Cas9-based therapies currently in clinical testing. This advancement enables high-potency genome editing with stringent specificity, reducing off-target risks for genetic medicines.
In Depth

Key Findings

The X-Editor (XE) demonstrates superior in vivo activity and exceptional genomic specificity compared to existing CRISPR systems. In tests using nonhuman primate livers, XE mRNA delivered via lipid nanoparticles (LNP) achieved higher editing efficiency at lower doses than preclinical data from Cas9-based therapies currently in clinical trials. Furthermore, full specificity assessments in primary human hepatocytes showed no detected off-target editing at doses tenfold above the on-target effective concentration (EC90).

Technical Details

The XE platform was created through iterative molecular engineering of the Cas12e protein and its guide RNA. The development process involved:

  • Screening tens of thousands of protein variants and guide designs.
  • Iterative testing and combination of beneficial mutations to increase potency.
  • The use of cryo-electron microscopy to identify the novel inter- and intramolecular interactions that drive the enhanced function.

These optimizations resulted in an enzyme with more than 100-fold higher editing activity in human cells compared to the original system.

Background & Context

While CRISPR-based modifications offer potential for one-time curative treatments, existing microbial nucleases like Cas9 evolved for antiviral defense rather than precision editing in human cells. This creates a challenge for in vivo delivery in large animals, where increasing potency at low doses is required to avoid unintended genomic modifications. The XE platform addresses these limitations by providing a naturally compact system suitable for delivery via either adeno-associated virus (AAV) or lipid nanoparticle (LNP) strategies.

Significance & Outlook

The engineering of the X-Editor establishes that high potency and stringent specificity can be jointly optimized in a compact CRISPR system. By allowing for lower dosing and greatly reducing off-target risks, this platform provides a new foundation for the development of advanced genetic medicines.

Source: https://doi.org/10.64898/2026.11.10.765514

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC